Healthcare entity
Negative sentiment reaches 57% here, compared with 26% across the 889-story beat baseline for the same window. Source depth averages 2.1 original sources per story, versus 3.5 across the same-window beat baseline. mifepristone is most often covered alongside FDA, which appears in 3 of these 7 stories.
Last mentioned: 1d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 57 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Negative sentiment reaches 57% here, compared with 26% across the 889-story beat baseline for the same window. Source depth averages 2.1 original sources per story, versus 3.5 across the same-window beat baseline. mifepristone is most often covered alongside FDA, which appears in 3 of these 7 stories. The 7 average consequence score is above the beat benchmark of 6 in the same window. That works out to roughly 0.3 stories per week across a 182-day span. regulation accounts for 4 of the 7 tracked stories, while 1 other category carries the remainder. We currently track 7 Healthcare stories that mention mifepristone, published between March 13, 2026 and September 10, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 889 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mifepristone. Shared-story counts are live from our verified record — not editorial picks.
Bill Signed into Law
Governor Inslee signs the measure, enabling the Department of Corrections to begin distribution to providers.
DOJ Missouri Filing
DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
Legislative Action
Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Louisiana Precedent
DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.
Legislation Introduced
State lawmakers introduce a bill to clarify the state's authority to distribute the stockpile to clinics.
Amended Complaint
AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.
Supreme Court Ruling
SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
Inventory Secured
The Washington Department of Corrections receives and stores the medication supply.
Stockpile Ordered
Governor Inslee directs the purchase of 30,000 doses of mifepristone following a Texas court ruling.
Pharmacy Certification
FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
Mail-Order Authorization
FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
Protocol Expansion
FDA extends usage window to 10 weeks and reduces required office visits from three to one.
Initial FDA Approval
FDA approves mifepristone for medical termination of pregnancy through seven weeks.
A Tucson OB-GYN reports 95% of abortion patients now choose telehealth after Arizona lifted state restrictions in February 2026. The Fifth Circuit's Louisiana v. FDA review could end that access nationally, forcing health systems to prepare for a return to in-person medication abortion.
Source: ijpr.org · wcsufm.org
Medication abortion accounts for at least 60% of U.S. abortions, and a lawsuit could restrict mifepristone prescribing in states where abortion is legal. Clinicians and telehealth providers face uncertainty over cross-border prescriptions and FDA rules.
Clinicians and public health advocates are sounding the alarm over a potential ban on mail-order mifepristone, which now accounts for 30% of U.S. abortions. Over 400 state lawmakers cite rural hospital closures and transportation barriers as evidence that ending telehealth abortion would create a healthcare crisis for millions.
Source: Alanna Vagianos (us) · Alanna Vagianos (in)
Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users.
Washington Governor Jay Inslee has signed legislation allowing the state to efficiently distribute its 30,000-dose stockpile of mifepristone to healthcare providers. The move solidifies the state's role as a direct supplier of reproductive healthcare in response to ongoing federal legal uncertainty.
The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
mifepristone is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
